Tofacitinib for the treatment of ulcerative colitis.

Abstract:

INTRODUCTION:New generations of small molecules are being developed for the treatment of ulcerative colitis. Among them, tofatinib (a Janus kinase (JAK) inhibitor) has demonstrated efficacy for inducing and maintaining remission and achieving mucosal healing with a reasonable safety profile. Oral administration is attractive for patients and lack of immunogenicity represents an advantage over biologic drugs. Areas covered: This review discusses the molecular aspects of the JAK-STAT pathway; the mechanism of action of tofacitinib pertinent to ulcerative colitis and the evidence on the efficacy of tofacitinib for achieving clinically relevant outcomes, including clinical remission, mucosal healing, and normalization of quality of life, as well as safety aspects with special attention to adverse events related to the mode of action of the drug. Expert commentary: Tofacitinib will be the first drug on the class of JAK inhibitors to be available for treatment of ulcerative colitis. The efficacy of the drug, with a rapid onset of action even in cases of severe colitis, oral administration, and possibility to use the drug intermittently without generating immunogenicity, will bring about a redesign of current treatment paradigms for ulcerative colitis.

authors

Fernández-Clotet A,Castro-Poceiro J,Panés J

doi

10.1080/1744666X.2018.1532291

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

881-892

issue

11

eissn

1744-666X

issn

1744-8409

journal_volume

14

pub_type

杂志文章,评审
  • New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

    abstract:INTRODUCTION:Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1454835

    authors: Carrascosa JM,Del-Alcazar E

    更新日期:2018-04-01 00:00:00

  • CD4+CD25+ regulatory T-cell therapy.

    abstract::Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) expressing forkhead transcript factor box P3 have been established as a key regulator for the control of autoimmunity. A growing body of experiments in animal models has provided compelling evidence that the adoptive transfer of CD4(+)CD25(+) Tregs can cure ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.3.387

    authors: Jiang S,Lechler RI,Lombardi G

    更新日期:2006-05-01 00:00:00

  • Targeted gene therapy of autoimmune diseases: advances and prospects.

    abstract::Idealized gene therapy of autoimmune diseases would mean getting the right drug to the right place at the right time to affect the right mechanism of action. In other words, a specific gene therapy strategy needs to have functional, spatial and temporal specificity. Functional specificity implies targeting the cellula...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.1.3.385

    authors: Creusot RJ,Fathman CG,Müller-Ladner U,Tarner IH

    更新日期:2005-09-01 00:00:00

  • Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.

    abstract:INTRODUCTION:Common variable immunodeficiency (CVID) comprises a large heterogeneous group of patients with primary antibody deficiency. Areas covered: The affected patients are characterized by increased susceptibility to infections and low levels of serum immunoglobulin. However, enteropathy, granulomatous organ infi...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1224664

    authors: Azizi G,Abolhassani H,Asgardoon MH,Alinia T,Yazdani R,Mohammadi J,Rezaei N,Ochs HD,Aghamohammadi A

    更新日期:2017-02-01 00:00:00

  • Determinants of thyroid autoantibody production in Hashimoto's thyroiditis.

    abstract::Hashimoto's thyroiditis (HT) is the most prevalent thyroid autoimmune disorder, characterized by the presence of specific thyroid autoantibodies (TAb). The development of autoimmunity, including TAb production and clinical presentation of HT, is determined by a complex interplay of genetic susceptibility and several e...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.2.217

    authors: Zaletel K

    更新日期:2007-03-01 00:00:00

  • A case for antibiotic perturbation of the microbiota leading to allergy development.

    abstract::The use of antibiotics to treat pathogenic bacterial infections has been one of the greatest contributions to human health, yet antibiotic use also perturbs the communities of commensal and symbiotic bacteria that reside in the intestine of mammals. The microbiota are critical for normal immune development and for mai...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.851603

    authors: Reynolds LA,Finlay BB

    更新日期:2013-11-01 00:00:00

  • Recent insights into CD4+ T-cell specificity and function in type 1 diabetes.

    abstract::Type 1 diabetes (T1D) is caused by T-cell-mediated destruction of the insulin-producing beta-cells in the pancreas. Genetic and immunological evidence from humans and mouse models indicates that CD4(+) T cells play a crucial role in the development and prevention of T1D. The dichotomy between CD4(+) T regulatory and e...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.4.557

    authors: Mannering SI,Brodnicki TC

    更新日期:2007-07-01 00:00:00

  • The pathogenesis of the secondary forms of autoimmune inner ear disease (AIED): advancing beyond the audiogram data.

    abstract:INTRODUCTION:Autoimmune Inner Ear Disease (AIED) can be of a primary or secondary type. To date, a clear pathogenesis of the disease is still not available. Focusing on the secondary forms of AIED, the aim of this review is to (i) assess and describe the hearing involvement in patients affected by autoimmune diseases, ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2021.1879640

    authors: Corazzi V,Hatzopoulos S,Bianchini C,Skarżyńska MB,Pelucchi S,Skarżyński PH,Ciorba A

    更新日期:2021-01-21 00:00:00

  • Tuberculosis in the course of sarcoidosis treatment: is genotyping necessary for personalized therapy?

    abstract::Pathological similarities between sarcoidosis (SA) and tuberculosis (TB) suggest that mycobacterial antigen(s), in genetically different predisposed hosts, may be a cause of SA. The authors' work and other published comparative analyses of HLA and non-HLA alleles in patients with SA or TB from different ethnic groups ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.13.8

    authors: Dubaniewicz A,Zimmermann A,Dudziak M,Typiak M,Skotarczak M

    更新日期:2013-04-01 00:00:00

  • Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.

    abstract::Glucocorticoids are indispensable for the treatment of systemic inflammatory diseases such as rheumatoid arthritis (RA), though their beneficial effects have to be balanced with potential complications arising from high doses, prolonged use or dose splitting. A glucocorticoid formulation (modified-release prednisone) ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.95

    authors: Alten R

    更新日期:2012-02-01 00:00:00

  • Perspectives on complementary and alternative therapies in asthma.

    abstract::Asthma is a chronic disease that affects millions of individuals living in the USA. Proper asthma management is essential for controlling asthma symptoms and exacerbations. In recent years, however, there has been increased recognition of individuals using complementary and alternative medicine (CAM) to treat asthma. ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.6.703

    authors: Adams SK,Koinis-Mitchell D

    更新日期:2008-11-01 00:00:00

  • The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook.

    abstract::Recent epidemiological studies estimated that more than 30% of European suffer from allergic rhinitis or conjunctivitis, while up to 20% suffer from asthma and 15% from allergic skin conditions, while for many other regions the prevalence is increasing. Allergen immunotherapy represents the only available treatment th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.977260

    authors: Pajno GB,Nadeau KC,Passalacqua G,Caminiti L,Hobson B,Jay DC,Arasi S,Chiera F,Salzano G

    更新日期:2015-01-01 00:00:00

  • Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.

    abstract::Introduction: The present status of amifampridine (AFP) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) is reviewed. Areas covered: All relevant literature identified through a PubMed search under treatment of LEMS, aminopyridine, and amifampridine are reviewed. An expert opinion on AFP was formulated. E...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2020.1670061

    authors: Oh SJ

    更新日期:2019-10-01 00:00:00

  • The roles of myeloid-derived suppressor cells in transplantation.

    abstract::CD11b(+)Gr1(+) myeloid-derived suppressor cells (MDSCs) are an important regulatory innate cell population and have significant inhibitory effect on T cell-mediated responses. In addition to their negative role in cancer development, MDSCs also exert strong regulatory effects on transplantation and autoimmunity. In ma...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.948424

    authors: Wu T,Zhao Y,Zhao Y

    更新日期:2014-10-01 00:00:00

  • HLA associations and Löfgren's syndrome.

    abstract::Patients with sarcoidosis can be subgrouped according to organ engagement and clinical manifestations. One such subgroup is Löfgren's syndrome (LS), constituting a distinct group of sarcoidosis patients with typical clinical manifestations, separate genetic associations and an immune response that seems to differ from...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.76

    authors: Grunewald J

    更新日期:2012-01-01 00:00:00

  • Remission maintenance in ANCA-associated vasculitis: does one size fit all?

    abstract::Introduction: The majority of the patients with anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) achieve remission with effective induction therapy. Therefore, prevention of relapses and avoiding long-term damage and treatment-related toxicity are major challenges.Areas covered: This review ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2020.1693260

    authors: Berti A,Specks U

    更新日期:2019-12-01 00:00:00

  • Remestemcel-L for the treatment of graft versus host disease.

    abstract:INTRODUCTION:Remestemcel-L, a third-party, off-the-shelf preparation of bone-marrow derived mesenchymal stromal cells (MSCs), has been developed for experimental use in acute graft-versus-host disease (aGvHD) and other immune-mediated conditions. Several preclinical and clinical studies have indeed suggested the potent...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1208086

    authors: Locatelli F,Algeri M,Trevisan V,Bertaina A

    更新日期:2017-01-01 00:00:00

  • Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.

    abstract::Conventional myeloablative conditioning regimens prior to hematopoietic cell transplantation (HCT) are associated with significant transplant-related morbidity and mortality in children affected by primary immunodeficiency disorders. Reduced-intensity conditioning regimens have been extensively used without severe acu...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.9

    authors: Chiesa R,Veys P

    更新日期:2012-03-01 00:00:00

  • Regulatory T cells: the future of autoimmune disease treatment.

    abstract::Introduction: CD4 + T regulatory cells (Tregs) have been described as the most potent immunosuppressive cells in the human body. They have been found to control autoimmunity, and clinical attempts have been made to apply them to treat autoimmune diseases. Some specific pathways utilized by Tregs in the regulation of i...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1620602

    authors: Ryba-Stanisławowska M,Sakowska J,Zieliński M,Ławrynowicz U,Trzonkowski P

    更新日期:2019-07-01 00:00:00

  • Adalimumab for the treatment of uveitis.

    abstract:INTRODUCTION:Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered: The aim of this review is to summarize the research which demonstrat...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2017.1288097

    authors: LaMattina KC,Goldstein DA

    更新日期:2017-03-01 00:00:00

  • Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?

    abstract::The course of inflammatory bowel diseases is heterogeneous and varies over time. Therefore, the search for predictive factors has increasingly become the focus of research. Mucosal healing has emerged as an important objective, as evidence indicates that it is associated with improved disease outcome. Nevertheless, ma...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.824675

    authors: Miheller P,Mandel MD,Mullner K,Lakatos PL

    更新日期:2013-09-01 00:00:00

  • Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?

    abstract::Epigenetic modifications of gene expression comprise modifications of DNA by DNA methylation and modifications of the histone proteins by acetylation, methylation, SUMOylation or phosphorylation. DNA methylation in the promoter region of genes represses gene transcription. Histone modifications influence the structure...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.37

    authors: Jüngel A,Distler JH,Gay S,Distler O

    更新日期:2011-07-01 00:00:00

  • Leptospirosis: current situation and trends of specific laboratory tests.

    abstract::Leptospirosis is re-emerging as a worldwide zoonosis and is caused by bacteria of the genus Leptospira. Human leptospirosis is associated with high temperature and humidity. Laboratory tests are indispensible for the early diagnosis and proper disease management. The demand for suitable leptospirosis point-of-care dia...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.110

    authors: Schreier S,Doungchawee G,Chadsuthi S,Triampo D,Triampo W

    更新日期:2013-03-01 00:00:00

  • Tests for evaluating non-immediate allergic drug reactions.

    abstract::Non-immediate drug reactions (NIR) are induced by specific immunological mechanisms and involve the recognition of hapten molecules by the immune system, with the participation of dendritic cells and other antigen-presenting cells. This process is followed by an effector response that can induce several clinical entit...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.966691

    authors: Perkins JR,Ariza A,Blanca M,Fernández TD

    更新日期:2014-11-01 00:00:00

  • Prediction and management of cardiovascular outcomes in systemic lupus erythematosus.

    abstract::Atherosclerosis is the major cause of cardiovascular disease (CVD), which represents the major cause of death. During recent years, it has become clear that atherosclerosis is a chronic inflammatory condition where immunity could play an important role. Usually, it is when atherosclerotic plaques rupture that CVD foll...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.993970

    authors: Frostegård J

    更新日期:2015-02-01 00:00:00

  • Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.

    abstract::Methotrexate (MTX) is the key treatment in juvenile idiopathic arthritis (JIA). Nevertheless, MTX is not always sufficiently efficacious and can lead to adverse effects, which compromises complete disease control. In such cases, combination therapies with biologicals are given, even at MTX start, before knowing the pa...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.916617

    authors: Ćalasan MB,Wulffraat NM

    更新日期:2014-07-01 00:00:00

  • Use of rituximab in multiple sclerosis: current progress and future perspectives.

    abstract::In recent years, new insights into the immunological pathways in multiple sclerosis (MS) have been detected. This increasing knowledge has led to more distinct treatment options in modifying the disease course of MS. In 2006, natalizumab, an alpha4-integrin monoclonal antibody, introduced a new era of MS treatment. An...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.5.573

    authors: Reske D,Haupt WF

    更新日期:2008-09-01 00:00:00

  • Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains.

    abstract:BACKGROUND:X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Patients suffer from recurrent bacterial infections from early childhood, and require lifelong immunoglobulin replacement therapy. Mutations in BTK (Bruton's Tyrosine Kinase) are associated with this phenotype. S...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2018.1413349

    authors: Carrillo-Tapia E,García-García E,Herrera-González NE,Yamazaki-Nakashimada MA,Staines-Boone AT,Segura-Mendez NH,Scheffler-Mendoza SC,O Farrill-Romanillos P,Gonzalez-Serrano ME,Rodriguez-Alba JC,Santos-Argumedo L,Berron-Ruiz L,Sanc

    更新日期:2018-01-01 00:00:00

  • Treatment and monitoring of hypersensitivity pneumonitis.

    abstract:INTRODUCTION:Hypersensitivity pneumonitis (HP) is an immunologically induced lung disease that develops after inhalation of certain environmental antigens only in subjects with susceptibility to antigens. Therefore, both environmental and host immunological factors play important roles in the aetiology and pathogenesis...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1182426

    authors: Miyazaki Y,Tsutsui T,Inase N

    更新日期:2016-09-01 00:00:00

  • Adult and pediatric clinical trials of sublingual immunotherapy in the USA.

    abstract::Specific allergen immunotherapy has been practiced for allergic rhinoconjunctivitis for over 100 years and is the only treatment option that is disease modifying. In the USA, immunotherapy is usually administered via subcutaneous injection; this is the only route with a US FDA-approved formulation. There is growing in...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.41

    authors: Park D,Daher N,Blaiss MS

    更新日期:2012-08-01 00:00:00